G. A. Mkrtchyan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
G. A. Mkrtchyan has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- A. I. Bespalova
National Medical Research Center of Oncology, Ministry of Health of Russia
5 shared publications - D. Yu. Yurchenko
National Medical Research Center of Oncology, Ministry of Health of Russia
5 shared publications - Yulia Yu. Kozel
National Medical Research Center of Oncology, Ministry of Health of Russia
5 shared publications - E. E. Pak
National Medical Research Center of Oncology, Ministry of Health of Russia
4 shared publications - M. V. Starzhetskaya
National Medical Research Center of Oncology, Ministry of Health of Russia
4 shared publications - O. P. Popovyan
National Medical Research Center of Oncology, Ministry of Health of Russia
4 shared publications
Latest Publications
- Open Access
- 21 September 2025
- Published by Publishing House ABV Press in MD-Onco
- Vol. 5 (3) , 80-88
The impact of chemotherapy on pituitary hormonal function in pubertal children with Hodgkin’s lymphoma
Background. Endocrine disorders are a significant long-term complication in children who have undergone anti-cancer treatment. Despite the relevance of this issue, the effects of chemotherapy (CT) on pituitary hormonal function in pubertal children with Hodgkin’s lymphoma (HL) remain poorly understood.Aim. To evaluate the levels of pituitary hormones (somatotropic (growth) hormone (GH), thyroid-stimulating (TSH), adrenocorticotropic (ACTH), luteinizing (LH), follicle-stimulating (FSH) hormones, prolactin) in pubertal children with HL before and after chemotherapy. Materials and methods. The study included 40 pubertal children (11–17 years old, median 13.65 years) diagnosed with HL (20 (50 %) boys and 20 (50 %) girls) – main group. The control group comprised 40 conditionally healthy children of the same age range (median age 15.25 years) with equal gender distribution. Blood samples from the HL group were collected before chemotherapy and after its completion (prior to radiotherapy). Hormone levels (GH, TSH, ACTH, LH, FSH, prolactin) were measured using standard radioimmunoassay and enzyme-linked immunosorbent assay kits. Reference values were based on hormone levels in the control group. Statistical analysis was performed using Statistica 10.Results. In girls with HL, pre-treatment levels of LH, FSH, and the LH/FSH ratio were elevated by 1.8-, 1.4-, and 1.3-fold, respectively, compared to the norm (p 0.05). GH and ACTH levels were 1.6and 3.1-fold below normal, respectively (p 0.05). After CT, LH levels decreased by 2.8-fold from baseline and by 1.5-fold relative to the norm, while FSH levels remained elevated at 1.6-fold above the norm (p 0.05). The LH/FSH ratio dropped by 2.6-fold relative to the norm and by 3.2-fold compared to baseline. Prolactin levels post-CT were 1.7-fold above the norm and 1.5-fold above baseline (p 0.05). GH levels were 7.8-fold lower than normal and 4.8-fold below baseline, whereas ACTH levels increased by 6.7-fold over baseline and were twice the normal level.In boys with HL, pre-treatment LH levels and LH/FSH ratio were 1.5and 1.4-fold below normal, respectively (p 0.05). Prolactin was 1.8-fold higher than normal (p 0.05), and GH was 3.6-fold below normal. After CT, LH increased by 1.4-fold compared to baseline, reaching reference values (p 0.05).Based on FSH levels, patients were divided into two subgroups: in 50 %, FSH remained within the normal range, while in the other 50 %, it increased ten-fold. The LH/FSH ratio remained normal in the first subgroup but was 11-fold below normal and 7.8-fold below baseline in the second. Post-treatment prolactin levels were 3.6-fold above normal and twice the baseline level. GH increased threefold from baseline and normalized. ACTH exceeded both normal and baseline levels two-fold. TSH levels decreased by 1.8-fold compared to both the norm and baseline (p 0.05).Conclusion. The development of HL in pubertal children is associated with suppression of adenohypophyseal function and an imbalance in the synthesis of tropic hormones. Antitumor therapy does not generally restore normal hormone levels, which may be due to dysregulation of the central endocrine axes or the presence of extrapituitary sources of hormone production.
- 21 September 2025
- Published by Publishing House ABV Press in MD-Onco
- Vol. 5 (3) , 80-88
Open AccessThe impact of chemotherapy on pituitary hormonal function in pubertal children with Hodgkin’s lymphoma
Background. Endocrine disorders are a significant long-term complication in children who have undergone anti-cancer treatment. Despite the relevance of this issue, the effects of chemotherapy (CT) on pituitary hormonal function in pubertal children with Hodgkin’s lymphoma (HL) remain poorly understood.Aim. To evaluate the levels of pituitary hormones (somatotropic (growth) hormone (GH), thyroid-stimulating (TSH), adrenocorticotropic (ACTH), luteinizing (LH), follicle-stimulating (FSH) hormones, prolactin) in pubertal children with HL before and after chemotherapy. Materials and methods. The study included 40 pubertal children (11–17 years old, median 13.65 years) diagnosed with HL (20 (50 %) boys and 20 (50 %) girls) – main group. The control group comprised 40 conditionally healthy children of the same age range (median age 15.25 years) with equal gender distribution. Blood samples from the HL group were collected before chemotherapy and after its completion (prior to radiotherapy). Hormone levels (GH, TSH, ACTH, LH, FSH, prolactin) were measured using standard radioimmunoassay and enzyme-linked immunosorbent assay kits. Reference values were based on hormone levels in the control group. Statistical analysis was performed using Statistica 10.Results. In girls with HL, pre-treatment levels of LH, FSH, and the LH/FSH ratio were elevated by 1.8-, 1.4-, and 1.3-fold, respectively, compared to the norm (p 0.05). GH and ACTH levels were 1.6and 3.1-fold below normal, respectively (p 0.05). After CT, LH levels decreased by 2.8-fold from baseline and by 1.5-fold relative to the norm, while FSH levels remained elevated at 1.6-fold above the norm (p 0.05). The LH/FSH ratio dropped by 2.6-fold relative to the norm and by 3.2-fold compared to baseline. Prolactin levels post-CT were 1.7-fold above the norm and 1.5-fold above baseline (p 0.05). GH levels were 7.8-fold lower than normal and 4.8-fold below baseline, whereas ACTH levels increased by 6.7-fold over baseline and were twice the normal level.In boys with HL, pre-treatment LH levels and LH/FSH ratio were 1.5and 1.4-fold below normal, respectively (p 0.05). Prolactin was 1.8-fold higher than normal (p 0.05), and GH was 3.6-fold below normal. After CT, LH increased by 1.4-fold compared to baseline, reaching reference values (p 0.05).Based on FSH levels, patients were divided into two subgroups: in 50 %, FSH remained within the normal range, while in the other 50 %, it increased ten-fold. The LH/FSH ratio remained normal in the first subgroup but was 11-fold below normal and 7.8-fold below baseline in the second. Post-treatment prolactin levels were 3.6-fold above normal and twice the baseline level. GH increased threefold from baseline and normalized. ACTH exceeded both normal and baseline levels two-fold. TSH levels decreased by 1.8-fold compared to both the norm and baseline (p 0.05).Conclusion. The development of HL in pubertal children is associated with suppression of adenohypophyseal function and an imbalance in the synthesis of tropic hormones. Antitumor therapy does not generally restore normal hormone levels, which may be due to dysregulation of the central endocrine axes or the presence of extrapituitary sources of hormone production.
- Open Access
- 14 November 2024
- Published by ANO -Perspective of Oncology in South Russian Journal of Cancer
- Vol. 5 (4) , 38-45
A case of a fifteen-year-old patient suffering from rare adenocystic lung carcinoma bronchoplastic surgery
Adenoid cystic carcinoma of the lung is a relatively rare malignant tumor, accounting for 0.04–0.2 % of all primary malignant tumors of the respiratory system. This carcinoma can occur at any age, but it is more common in the 40–60 age group and usually in women. The main treatment method for adenoid cystic carcinoma is surgical. Since tumors of this histological form are often centrally located, options for bronchoplastic operations are considered. In childhood, adenoid cystic carcinoma is extremely rare, and performing bronchoplastic lobectomies in children is associated with several difficulties, such as the smaller diameter of the bronchi compared to adult patients, complicating surgical intervention and subsequent rehabilitation. This clinical case demonstrates the experience of performing a bronchoplastic operation on a 15-year-old patient at the Department of Thoracic Oncology of the National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation. The patient was hospitalized complaining of prolonged cough, shortness of breath, and chest pain. Adenoid cystic carcinoma of the central type was identified during diagnostics, which included bronchoscopy, computed tomography, and biopsy. The surgical intervention involved performing a bronchoplastic lobectomy, during which the affected lobe of the lung was removed with resection and reconstruction of the bronchus. The operation was performed taking into account the anatomical features of the child's body, which required high precision and surgical skills. The postoperative period proceeded without significant complications, and the patient was under the supervision of a multidisciplinary team of specialists.This clinical case provides a detailed description of the results of preoperative diagnostic measures, the stages of the operation, and the postoperative follow-up results. Special attention was paid to the difficulties associated with the small diameter of the bronchi in children, which required the use of specialized instruments and techniques. The importance of using modern diagnostic and treatment methods, as well as close interdisciplinary interaction, is emphasized for a successful treatment outcome.The experience of performing such operations in childhood is extremely important for improving the quality and safety of surgical treatment of adenoid cystic carcinoma and other rare tumors in children. Further observations will be described in stages.
- 14 November 2024
- Published by ANO -Perspective of Oncology in South Russian Journal of Cancer
- Vol. 5 (4) , 38-45
Open AccessA case of a fifteen-year-old patient suffering from rare adenocystic lung carcinoma bronchoplastic surgery
Adenoid cystic carcinoma of the lung is a relatively rare malignant tumor, accounting for 0.04–0.2 % of all primary malignant tumors of the respiratory system. This carcinoma can occur at any age, but it is more common in the 40–60 age group and usually in women. The main treatment method for adenoid cystic carcinoma is surgical. Since tumors of this histological form are often centrally located, options for bronchoplastic operations are considered. In childhood, adenoid cystic carcinoma is extremely rare, and performing bronchoplastic lobectomies in children is associated with several difficulties, such as the smaller diameter of the bronchi compared to adult patients, complicating surgical intervention and subsequent rehabilitation. This clinical case demonstrates the experience of performing a bronchoplastic operation on a 15-year-old patient at the Department of Thoracic Oncology of the National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation. The patient was hospitalized complaining of prolonged cough, shortness of breath, and chest pain. Adenoid cystic carcinoma of the central type was identified during diagnostics, which included bronchoscopy, computed tomography, and biopsy. The surgical intervention involved performing a bronchoplastic lobectomy, during which the affected lobe of the lung was removed with resection and reconstruction of the bronchus. The operation was performed taking into account the anatomical features of the child's body, which required high precision and surgical skills. The postoperative period proceeded without significant complications, and the patient was under the supervision of a multidisciplinary team of specialists.This clinical case provides a detailed description of the results of preoperative diagnostic measures, the stages of the operation, and the postoperative follow-up results. Special attention was paid to the difficulties associated with the small diameter of the bronchi in children, which required the use of specialized instruments and techniques. The importance of using modern diagnostic and treatment methods, as well as close interdisciplinary interaction, is emphasized for a successful treatment outcome.The experience of performing such operations in childhood is extremely important for improving the quality and safety of surgical treatment of adenoid cystic carcinoma and other rare tumors in children. Further observations will be described in stages.
- 1 June 2023
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 102 (3)
ASSESSMENT OF THE EXPRESSION OF MMР-2, MMР-9 AND FIBRONECTIN MARKERS AS PROGRESSION PREDICTORS IN THE PRIMARY TUMOR TISSUE OF LOCALIZED AND GENERALIZED FORMS OF EWING’S SARCOMA IN CHILDREN AND ADOLESCENTS
Despite processes of epithelial-mesenchymal transition (EMT) that underlie the development of malignant tumors are described widely, the mesenchymal-epithelial transition (MET), which in its turn promotes the metastasis of various tumors, including Ewing's sarcoma (ES), had been studied very little as yet. Within the framework of pediatric oncopathology, ES is one of the most aggressive and metastatic tumors of bones and soft tissues. The purpose of this research was to analyze the features of the expression of markers of the metastatic phenotype of tumor cells MMP2, MMP9 and FN1 in the tissue of the primary tumor in children and adolescents with various forms of ES prevalence. Materials and methods used: 67 patients with localized (n=26) and generalized (n=41) forms of ES aged 0 to 18 y/o, who have been treated at the Pediatric Oncology Department of the National Medical Research Center for Oncology of the Ministry of Healthcare of Russia (Rostov-on-Don, Russia) in Jan. 2009-Dec. 2019. MMP2, MMP9 and FN1 markers were studied by immunohistochemical method in the primary tumor tissue obtained at the stage of process verification and radical surgical treatment after multi-course polychemotherapy (PCT). Results: MMP2 expression in groups with localized and generalized ES before treatment was 4 (p=0.018) and 4.4 (p=0.001) times higher compared to those after treatment. MMP9 expression in the group with generalized ES before treatment prevailed 1.5 times (p=0.020) in comparison with the group after treatment. The median FN1 expression, on the contrary, was 1.2 times lower in the group with generalized ES before treatment than after (p=0.799). Conclusions: determining the expression level of the MMP2 marker in the primary tumor of ES patients can be used to predict the course of the disease and to evaluate the effect of treatment. Whilst markers MMP9 and FN1 require further expanded research.
- 1 June 2023
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 102 (3)
ASSESSMENT OF THE EXPRESSION OF MMР-2, MMР-9 AND FIBRONECTIN MARKERS AS PROGRESSION PREDICTORS IN THE PRIMARY TUMOR TISSUE OF LOCALIZED AND GENERALIZED FORMS OF EWING’S SARCOMA IN CHILDREN AND ADOLESCENTS
Despite processes of epithelial-mesenchymal transition (EMT) that underlie the development of malignant tumors are described widely, the mesenchymal-epithelial transition (MET), which in its turn promotes the metastasis of various tumors, including Ewing's sarcoma (ES), had been studied very little as yet. Within the framework of pediatric oncopathology, ES is one of the most aggressive and metastatic tumors of bones and soft tissues. The purpose of this research was to analyze the features of the expression of markers of the metastatic phenotype of tumor cells MMP2, MMP9 and FN1 in the tissue of the primary tumor in children and adolescents with various forms of ES prevalence. Materials and methods used: 67 patients with localized (n=26) and generalized (n=41) forms of ES aged 0 to 18 y/o, who have been treated at the Pediatric Oncology Department of the National Medical Research Center for Oncology of the Ministry of Healthcare of Russia (Rostov-on-Don, Russia) in Jan. 2009-Dec. 2019. MMP2, MMP9 and FN1 markers were studied by immunohistochemical method in the primary tumor tissue obtained at the stage of process verification and radical surgical treatment after multi-course polychemotherapy (PCT). Results: MMP2 expression in groups with localized and generalized ES before treatment was 4 (p=0.018) and 4.4 (p=0.001) times higher compared to those after treatment. MMP9 expression in the group with generalized ES before treatment prevailed 1.5 times (p=0.020) in comparison with the group after treatment. The median FN1 expression, on the contrary, was 1.2 times lower in the group with generalized ES before treatment than after (p=0.799). Conclusions: determining the expression level of the MMP2 marker in the primary tumor of ES patients can be used to predict the course of the disease and to evaluate the effect of treatment. Whilst markers MMP9 and FN1 require further expanded research.
- 1 June 2023
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 102 (3)
ASSESSMENT OF THE EXPRESSION OF MMР-2, MMР-9 AND FIBRONECTIN MARKERS AS PROGRESSION PREDICTORS IN THE PRIMARY TUMOR TISSUE OF LOCALIZED AND GENERALIZED FORMS OF EWING’S SARCOMA IN CHILDREN AND ADOLESCENTS
Despite processes of epithelial-mesenchymal transition (EMT) that underlie the development of malignant tumors are described widely, the mesenchymal-epithelial transition (MET), which in its turn promotes the metastasis of various tumors, including Ewing's sarcoma (ES), had been studied very little as yet. Within the framework of pediatric oncopathology, ES is one of the most aggressive and metastatic tumors of bones and soft tissues. The purpose of this research was to analyze the features of the expression of markers of the metastatic phenotype of tumor cells MMP2, MMP9 and FN1 in the tissue of the primary tumor in children and adolescents with various forms of ES prevalence. Materials and methods used: 67 patients with localized (n=26) and generalized (n=41) forms of ES aged 0 to 18 y/o, who have been treated at the Pediatric Oncology Department of the National Medical Research Center for Oncology of the Ministry of Healthcare of Russia (Rostov-on-Don, Russia) in Jan. 2009-Dec. 2019. MMP2, MMP9 and FN1 markers were studied by immunohistochemical method in the primary tumor tissue obtained at the stage of process verification and radical surgical treatment after multi-course polychemotherapy (PCT). Results: MMP2 expression in groups with localized and generalized ES before treatment was 4 (p=0.018) and 4.4 (p=0.001) times higher compared to those after treatment. MMP9 expression in the group with generalized ES before treatment prevailed 1.5 times (p=0.020) in comparison with the group after treatment. The median FN1 expression, on the contrary, was 1.2 times lower in the group with generalized ES before treatment than after (p=0.799). Conclusions: determining the expression level of the MMP2 marker in the primary tumor of ES patients can be used to predict the course of the disease and to evaluate the effect of treatment. Whilst markers MMP9 and FN1 require further expanded research.
- 1 June 2023
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 102 (3)
ASSESSMENT OF THE EXPRESSION OF MMР-2, MMР-9 AND FIBRONECTIN MARKERS AS PROGRESSION PREDICTORS IN THE PRIMARY TUMOR TISSUE OF LOCALIZED AND GENERALIZED FORMS OF EWING’S SARCOMA IN CHILDREN AND ADOLESCENTS
Despite processes of epithelial-mesenchymal transition (EMT) that underlie the development of malignant tumors are described widely, the mesenchymal-epithelial transition (MET), which in its turn promotes the metastasis of various tumors, including Ewing's sarcoma (ES), had been studied very little as yet. Within the framework of pediatric oncopathology, ES is one of the most aggressive and metastatic tumors of bones and soft tissues. The purpose of this research was to analyze the features of the expression of markers of the metastatic phenotype of tumor cells MMP2, MMP9 and FN1 in the tissue of the primary tumor in children and adolescents with various forms of ES prevalence. Materials and methods used: 67 patients with localized (n=26) and generalized (n=41) forms of ES aged 0 to 18 y/o, who have been treated at the Pediatric Oncology Department of the National Medical Research Center for Oncology of the Ministry of Healthcare of Russia (Rostov-on-Don, Russia) in Jan. 2009-Dec. 2019. MMP2, MMP9 and FN1 markers were studied by immunohistochemical method in the primary tumor tissue obtained at the stage of process verification and radical surgical treatment after multi-course polychemotherapy (PCT). Results: MMP2 expression in groups with localized and generalized ES before treatment was 4 (p=0.018) and 4.4 (p=0.001) times higher compared to those after treatment. MMP9 expression in the group with generalized ES before treatment prevailed 1.5 times (p=0.020) in comparison with the group after treatment. The median FN1 expression, on the contrary, was 1.2 times lower in the group with generalized ES before treatment than after (p=0.799). Conclusions: determining the expression level of the MMP2 marker in the primary tumor of ES patients can be used to predict the course of the disease and to evaluate the effect of treatment. Whilst markers MMP9 and FN1 require further expanded research.
- Open Access
- 12 July 2021
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 8 (2) , 26-34
The experience of managing children and adolescents with Ewing’s sarcoma in the Pediatric Oncology Department of the Federal State Budgetary Institution “National Medical Research Center of Oncology”, Ministry of Health of Russia
Relevance. One of the leading positions among malignant tumors of the musculoskeletal system in children and adolescents has recently begun to be occupied by Ewing’s sarcoma (ES). The prognosis of patients suffering from this onconosology remains extremely unfavorable even in the absence of distant metastases and timely initiation of antitumor treatment. The authors present 10 years of experience in the management of pediatric and adolescent patients with ES in the pediatric oncology department of the National Medical Research Center of Oncology, Ministry of Health of Russia.Materials and methods. The study included pediatric and adolescent patients diagnosed with ES of I—IV stages of various localizations, who were treated in the Pediatric Oncology Department of the National Medical Research Center of Oncology, Ministry of Health of Russia in the period from 2009 to 2019. We analyzed 2- and 5-year overall (OS) and event-free (EFS) survival in patients who received combined and complex antitumor treatment for various forms of tumor dissemination according to the EURO-EWING 2008protocol, which included neo-and adjuvant polychemotherapy, including high-dose, radical surgical treatment, and also radiation therapy.Results. The median 5-year OS and EFS in the general group of the studied formulations was 60 and 17 months, respectively. The indicators of 2- and 5-year OS and EFS in patients of the general group were 80.6 % and 56.7 %, 38.6 % and 10.6 %, respectively. The volume of the performed antitumor treatment, as well as the form of the advanced tumor process, did not have a significant effect on OS and EFS indicators (p > 0.05). At the same time, the chances of developing ES in boys were statistically significantly higher by 2.2 times in comparison with girls (95 % confidence interval 1.1—4.3).Conclusion. The obtained OS and EFS indices indicate unsatisfactory results of anticancer therapy and extremely high aggressiveness of the biological behavior of the tumor, regardless of the form of spread of the tumor process.
- 12 July 2021
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 8 (2) , 26-34
Open AccessThe experience of managing children and adolescents with Ewing’s sarcoma in the Pediatric Oncology Department of the Federal State Budgetary Institution “National Medical Research Center of Oncology”, Ministry of Health of Russia
Relevance. One of the leading positions among malignant tumors of the musculoskeletal system in children and adolescents has recently begun to be occupied by Ewing’s sarcoma (ES). The prognosis of patients suffering from this onconosology remains extremely unfavorable even in the absence of distant metastases and timely initiation of antitumor treatment. The authors present 10 years of experience in the management of pediatric and adolescent patients with ES in the pediatric oncology department of the National Medical Research Center of Oncology, Ministry of Health of Russia.Materials and methods. The study included pediatric and adolescent patients diagnosed with ES of I—IV stages of various localizations, who were treated in the Pediatric Oncology Department of the National Medical Research Center of Oncology, Ministry of Health of Russia in the period from 2009 to 2019. We analyzed 2- and 5-year overall (OS) and event-free (EFS) survival in patients who received combined and complex antitumor treatment for various forms of tumor dissemination according to the EURO-EWING 2008protocol, which included neo-and adjuvant polychemotherapy, including high-dose, radical surgical treatment, and also radiation therapy.Results. The median 5-year OS and EFS in the general group of the studied formulations was 60 and 17 months, respectively. The indicators of 2- and 5-year OS and EFS in patients of the general group were 80.6 % and 56.7 %, 38.6 % and 10.6 %, respectively. The volume of the performed antitumor treatment, as well as the form of the advanced tumor process, did not have a significant effect on OS and EFS indicators (p > 0.05). At the same time, the chances of developing ES in boys were statistically significantly higher by 2.2 times in comparison with girls (95 % confidence interval 1.1—4.3).Conclusion. The obtained OS and EFS indices indicate unsatisfactory results of anticancer therapy and extremely high aggressiveness of the biological behavior of the tumor, regardless of the form of spread of the tumor process.
- Open Access
- 21 September 2020
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 7 (3) , 39-46-46
ZEB1 as an additional predictor of tumor progression in Ewingʼs sarcoma. Results of a morphological study on a population of children and adolescents
Relevance. Ewingʼs sarcoma (ES) is a classic representative of the extensive family of ES tumors, which occupies one of the leading positions among the malignant pathology of the musculoskeletal system in children and adolescents. This group is characterized by an extremely large variety of morphological, immunohistochemical, and molecular genetic characters among its representatives. The absence of specific pathognomonic markers for ES, as well as the presence of wide variability of clinical manifestations complicates the differential diagnosis. Materials and methods. The study included patients of childhood and adolescence with a localized and generalized form of ES/PNEТ of various localizations undergoing treatment in the conditions of the Department of Pediatric Oncology of the Federal State Budgetary Research Center for Oncology from 2009 to 2019. As the material, the tissue of the primary tumor of ES/PNEТ from paraffin blocks was used, obtained from 67 patients during the primary biopsy, as well as after the surgical stage as part of a combined or complex treatment. The expression of ZEB1 was determined immunohistochemically.Results. The highest average level of expression of ZEB1 protein was observed in group 4 with a generalized form of ES (surgical material) and amounted to 60.8 ± 2.2 %, the minimum level was detected in group 2 with a localized form of ES (surgical material) and amounted to 29.2 ± 3.0 %. Between groups 2 (localized form) and 4 (generalized form) statistically significant differences were noted (p = 0.026).Conclusion. As a result of an immunohistochemical study, the ZEB1 protein showed its prognostic significance when comparing groups with a localized and generalized form of ES (p = 0.026). The predominance of the expression level of ZEB1 protein in the group with the generalized form statistically significantly increased the chances of metastasis by 3.6 times (95 % CI 1.13-11.8).
- 21 September 2020
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 7 (3) , 39-46-46
Open AccessZEB1 as an additional predictor of tumor progression in Ewingʼs sarcoma. Results of a morphological study on a population of children and adolescents
Relevance. Ewingʼs sarcoma (ES) is a classic representative of the extensive family of ES tumors, which occupies one of the leading positions among the malignant pathology of the musculoskeletal system in children and adolescents. This group is characterized by an extremely large variety of morphological, immunohistochemical, and molecular genetic characters among its representatives. The absence of specific pathognomonic markers for ES, as well as the presence of wide variability of clinical manifestations complicates the differential diagnosis. Materials and methods. The study included patients of childhood and adolescence with a localized and generalized form of ES/PNEТ of various localizations undergoing treatment in the conditions of the Department of Pediatric Oncology of the Federal State Budgetary Research Center for Oncology from 2009 to 2019. As the material, the tissue of the primary tumor of ES/PNEТ from paraffin blocks was used, obtained from 67 patients during the primary biopsy, as well as after the surgical stage as part of a combined or complex treatment. The expression of ZEB1 was determined immunohistochemically.Results. The highest average level of expression of ZEB1 protein was observed in group 4 with a generalized form of ES (surgical material) and amounted to 60.8 ± 2.2 %, the minimum level was detected in group 2 with a localized form of ES (surgical material) and amounted to 29.2 ± 3.0 %. Between groups 2 (localized form) and 4 (generalized form) statistically significant differences were noted (p = 0.026).Conclusion. As a result of an immunohistochemical study, the ZEB1 protein showed its prognostic significance when comparing groups with a localized and generalized form of ES (p = 0.026). The predominance of the expression level of ZEB1 protein in the group with the generalized form statistically significantly increased the chances of metastasis by 3.6 times (95 % CI 1.13-11.8).
- Open Access
- 2 June 2020
- Published by ANO -Perspective of Oncology in South Russian Journal of Cancer
- Vol. 1 (2) , 13-21
THE ULTRASOUND DIAGNOSTICS POTENTIAL OF THE SMALL PELVIS TUMORS IN CHILDREN
ВОЗМОЖНОСТИ УЛЬТРАЗВУКОВОЙ ДИАГНОСТИКИ ОПУХОЛЕЙ МАЛОГО ТАЗА У ДЕТЕЙ
- 2 June 2020
- Published by ANO -Perspective of Oncology in South Russian Journal of Cancer
- Vol. 1 (2) , 13-21
Open AccessTHE ULTRASOUND DIAGNOSTICS POTENTIAL OF THE SMALL PELVIS TUMORS IN CHILDREN
ВОЗМОЖНОСТИ УЛЬТРАЗВУКОВОЙ ДИАГНОСТИКИ ОПУХОЛЕЙ МАЛОГО ТАЗА У ДЕТЕЙ
- Open Access
- 1 January 2019
- Published by Euroasian Scientific and Industrial Chamber, Ltd. in Современные проблемы науки и образования (Modern Problems of Science and Education)
- No. №6 2019,p. 9
CHILDHOOD EMBRYONAL TUMORS: STATE OF THE PROBLEM
- 1 January 2019
- Published by Euroasian Scientific and Industrial Chamber, Ltd. in Современные проблемы науки и образования (Modern Problems of Science and Education)
- No. №6 2019,p. 9
Open AccessCHILDHOOD EMBRYONAL TUMORS: STATE OF THE PROBLEM